Edition:
United States

Alcobra Ltd (ADHD.OQ)

ADHD.OQ on NASDAQ Stock Exchange Global Market

1.51USD
19 Oct 2017
Change (% chg)

$0.24 (+18.90%)
Prev Close
$1.27
Open
$1.70
Day's High
$2.17
Day's Low
$1.51
Volume
6,357,497
Avg. Vol
131,071
52-wk High
$2.57
52-wk Low
$0.83

Chart for

About

Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the... (more)

Overall

Beta: 1.52
Market Cap(Mil.): $35.00
Shares Outstanding(Mil.): 27.56
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 90.61 17.08
EPS (TTM): -- -- --
ROI: -- 2.45 11.26
ROE: -- 3.37 15.09

BRIEF-Alcobr, Arcturus Therapeutics agree to merge

* Proposed merger has been unanimously approved by boards of directors of both companies

Sep 27 2017

BRIEF-Alcobra Ltd Q2 loss per share $0.13

* Alcobra announces second quarter 2017 financial results and provides corporate update

Aug 11 2017

BRIEF-Alcobra announces cooperation agreement with Brosh Group

* Alcobra announces cooperation agreement with Brosh Group and board additions

Jun 12 2017

BRIEF-Alcobra names David Baker interim CEO, replacing Daniely

* Yaron Daniely to step down as chief executive officer, effective May 31, 2017

May 15 2017

BRIEF-Alcobra provides update on cancellation of extraordinary meeting called by Brosh Group

* Alcobra provides update on cancellation of extraordinary meeting called by Brosh Group

May 05 2017

BRIEF-Alcobra Ltd says mailed proxy materials for extraordinary general meeting of shareholders

* Alcobra Ltd - "mailed proxy materials for extraordinary general meeting of shareholders, called by Brosh Capital L.P. and certain of its affiliates"

Apr 24 2017

Earnings vs. Estimates